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Introduction
Approximately 55,000 new cases of pancreatic ductal 
adenocarcinoma (PDAC) are diagnosed annually in the 
United States. PDAC is projected to be the second leading 
cause of cancer-related death by 2030 (1). Current standard 
therapies for metastatic PDAC include FOLFIRINOX 
(5-FU/LV, irinotecan, oxaliplatin) with median overall 
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a subset of patients. These data encourage further exploration of aminopeptidase inhibitors in pancreatic 
cancer. 
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survival (mOS) of 11.1 months (2), and gemcitabine/
nab-paclitaxel with mOS 8.5 months (3). Given the 
considerable toxicity of FOLFIRINOX, a large percentage 
of patients with advanced PDAC receive gemcitabine-based 
regimens in the front-line setting. Five-FU/leucovorin 
(LV)/nanoliposomal-irinotecan (nal-IRI) is a second-line 
treatment option for patients who have progressed on a 
gemcitabine-based regimen, however median progression-
free survival (PFS) is modest at 3.1 months (4). Thus, there 
is great need for more effective regimens in the second or 
later lines of therapy.
Aminopeptidases are N-terminus directed peptidases that 
degrade peptides resulting from proteasomal degradation 
into free single amino acids, and are over-expressed in 
multiple malignancies where they provide a continual 
supply of free amino acids to support anabolic processes and 
cellular growth. Multiple aminopeptidases are expressed in 
most cells, including aminopeptidase N (APN), leukotriene 
A4 (LTA4) hydrolase, puromycin-sensitive aminopeptidase 
(PuSA) and leucine aminopeptidase (LAP) [reviewed in (5)]. 
Amino acid starvation or treatment with small molecule 
aminopeptidase inhibitors leads to depletion of the 
cellular free amino acid pool and inhibition of the mTOR 
(mammalian target of rapamycin) pathway, as well as a 
signature transcriptional response to up-regulate expression 
of genes involved in de novo amino acid biosynthesis; 
collectively, this constitutes the amino acid deprivation 
stress response (AADR) (6). 
Notably, aminopeptidase N (APN) is over-expressed in 
PDAC relative to benign pancreatic tissue, and higher expression 
levels of APN correlate with inferior overall survival (7,8). The 
aminopeptidase inhibitor tosedostat (CTI BioPharma, Seattle) 
has produced encouraging results in relapsed/refractory acute 
myeloid leukemia (AML) (9), and has been evaluated in a phase 
I study of advanced solid tumors demonstrating tolerability 
and preliminary efficacy, with 4 out of 40 patients experiencing 
stable disease for greater than 6 months, and one with renal 
cell carcinoma (RCC) experiencing a partial response (10). 
Given the high frequency of aminopeptidase over-expression in 
PDAC, and its correlation with poorer outcomes, we conducted 
a phase Ib/II trial combining tosedostat with capecitabine as a 
second-line regimen. 
Methods 
Study design and participants
This was a single center open-label phase Ib/II study in 
patients with locally advanced or metastatic PDAC to 
evaluate the safety and efficacy of tosedostat in combination 
with capecitabine. The study was conducted at Washington 
University in St. Louis, St. Louis MO, USA. All subjects 
gave their informed consent for inclusion before they 
participated in the study. The study was conducted in 
accordance with the Declaration of Helsinki, and the 
protocol was approved by the Ethics Committee of 
Washington University in St. Louis. Patients eligible for 
enrollment were at least 18 years of age, had histologically 
or cytologically proven metastatic or unresectable 
PDAC, and had progressed on or were intolerant of prior 
gemcitabine-based therapy. Inclusion criteria required 
ECOG performance status of 0–2, and adequate bone 
marrow and organ function [ANC >1,000/µL, platelets 
>100,000/µL, total bilirubin ≤2 mg/dL, creatinine 
≤2 mg/dL, AST or ALT ≤2.5× ULN (≤5× ULN in the 
setting of liver metastases)]. Exclusion criteria included 
prior chemotherapy or radiotherapy within two weeks 
of study entry, known brain metastases, prior treatment 
with aminopeptidase inhibitor, known dihydropyrimidine 
dehydrogenase deficiency (DPD), significant cardiovascular 
disease or known HIV positivity on combination anti-
retroviral therapy. The study protocol was approved by the 
Washington University Institutional Review Board (IRB 
#201503074), and all patients provided written informed 
consent. The study outcomes will not affect the future 
management of the patients involved. 
Procedures
Tosedostat is an oral drug, which was taken on an outpatient 
basis daily on a 21-day cycle, at approximately the same 
time every day with food. Dosing of tosedostat during the 
phase Ib (lead-in phase) followed a 3+3 dose de-escalation 
design beginning with tosedostat 120 mg oral twice daily 
(dose level 0) on days 1–21 of each 21-day cycle. Previous 
studies identified a maximum tolerated dose (MTD) of 
tosedostat of 320 mg daily, and 240 mg as the maximum 
accepted dose (10). As there are no significant overlapping 
toxicities between tosedostat and capecitabine, a dose of 
tosedostat 120 mg oral twice daily was chosen as the entry 
dose level. In the event of dose-limiting toxicity (DLT) at 
dose level 0, tosedostat was to be dose-reduced to 60 mg 
twice daily (dose level 1); no further dose-reductions were 
allowed. Capecitabine dosing began at the standard dose 
of 1,000 mg/m2 twice daily (dose level 0) on days 1–14 of 
each 21-day cycle. For adverse events that were deemed 
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related to capecitabine, dose reduction to 750 mg/m2 
twice daily (dose level 1) and 500 mg/m2 twice daily 
(dose level 2) were allowed. Dose re-escalation was not 
allowed. No pre-medications were required for either 
tosedostat or capecitabine. Toxicity monitoring by complete 
blood count (CBC) and comprehensive metabolic panel 
(CMP), and cardiac monitoring by troponin I or T, brain 
natriuretic peptide (BNP), electrocardiogram (ECG) and 
echocardiogram were performed on day 1 of each cycle. 
Tumor assessment by CA19-9 tumor marker was performed 
on day 1 of each cycle, and computed tomography (CT) 
scans were performed at the end of each even-numbered 
cycle. Safety assessments were done in compliance with 
the Washington University Institutional Data and Safety 
Monitoring Plan. The study principal investigator and 
research patient coordinator continuously monitored for 
serious toxicities on an ongoing basis. Patients were treated 
until progression of disease or unacceptable toxicity.
Outcomes
The primary endpoint of the phase Ib was the RP2D of the 
combination therapy. For the phase II portion of the study, 
the primary endpoint was the PFS of the combination 
therapy. 
Statistical analysis
OS was defined as the months from the date of treatment 
start to date of death. Alive patients were censored at the 
last known date of follow up. OS was estimated by the 
Kaplan-Meier method and the survival probabilities at some 
time points were provided. Treatment failure free survival 
(TFFS) duration was defined as the months from the date 
of treatment start to the date of treatment end; patients 
without related AE or withdrawal were censored at the date 
of treatment end. PFS was defined as the months from the 
date of treatment start to the date of progression; patients 
without progression were censored at the last known date of 
follow up. The initial study design planned for 36 patients, 
with a power of 0.8 to identify an increase of median PFS 
from 2 to 4 months at 0.05 significance level, assuming 
12 months of accrual and 6 months of follow-up.
Results
Between October 2015 and December 2017, 16 patients 
were enrolled on our phase Ib/II study of tosedostat with 
capecitabine, including six patients in phase Ib (the dose de-
escalation phase), and 10 patients in the phase II. The trial 
was closed to accrual prematurely on 12/20/2017 due to 
insufficient funding and drug supply from the manufacturer 
(CTI BioPharma). Patient demographics are presented 
in Table 1. The median age was 66 years old, with a slight 
predominance of female patients. The majority of patients 
had an ECOG performance status of 1. Fourteen patients 
had metastatic disease, one had locally advanced disease, 
and the presence of metastases was unknown for one 
patient. Typical sites of metastases were all represented 
(liver, omentum, peritoneum, lungs). A total of six patients 
were treated at the starting dose level of tosedostat 120mg 
twice daily with capecitabine 1,000 mg/m2 twice daily in the 
phase Ib portion, and one patient experienced a DLT (grade 
3 acute coronary syndrome) (Table 2), thus tosedostat 120mg 
twice daily was identified as the RP2D. There were a total 
of five grade 3 treatment-related adverse events observed 
(acute coronary syndrome, nausea, prolonged QTc interval, 
Table 1 Characteristics of the patients at baseline
Characteristics N=16
Age, median [range] 66 [42–73]
Sex, n (%)
Male 7 (43.8)
Female 9 (56.3)
Ethnicity, n (%)
Caucasian 15 (93.8)
African American 1 (6.3)
ECOG PS, n (%)
0 1 (6.3)
1 15 (93.8)
2 0
Prior systemic therapy, n (%)
Gemcitabine 1 (6.3)
Gemcitabine/nab-pac* 6 (37.0)
Gemcitabine/nab-pac/indoximod 5 (31.0)
Gemcitabine/nab-pac/radiation 1 (6.3)
Gemcitabine/nab-pac/VS4718 1 (6.3)
Gemcitabine/nab-pac followed by 5-FU/XRT** 1 (6.3)
CA19-9, mean [min, max] 1,255 [1–8,803]
Percentages might not total 100% due to rounding. *Nab-pac, 
nanoparticle albumin-bound paclitaxel; **XRT, radiation.
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diarrhea, fatigue). Among six patients in the phase Ib part, 
three discontinued treatment due to toxicity [grade 3 
fatigue, acute MI prior to assessment of treatment response, 
and grade 2 decreased ejection fraction (EF)] and three due 
to disease progression. One of 10 patients in the phase II 
cohort experienced grade-3 toxicity (QTc prolongation); 
no grade-4 or -5 toxicities were observed in the phase II 
cohort (Table 2). No deaths were attributed to tosedostat. 
The study protocol required monitoring of cardiac EF, 
mandating holding, dose-reduction or discontinuation of 
tosedostat for grade 2 or 3 decreases in LV EF. Including 
the patient in the phase Ib cohort, a total of 5 of 16 patients 
(31%) came off study due to grade 2 decreased EF, all of 
which were asymptomatic and self-resolved with holding 
of tosedostat. The average time to worsening of EF was 
65 days, and average time to resolution was 30 days. 
Figure 1 shows treatment failure free survival (TFFS) 
and duration on study. The median TFFS was 3 months, 
and eight patients remained on study with stable disease 
for greater than 3 months. No radiographic partial (PR) or 
complete (CR) responses were observed. Sixty-two percent 
of patients (10/16) had a best response of stable disease, 
and 11/16 evaluable patients discontinued treatment due 
to disease progression. The median PFS was 7.0 months 
(Figure 2).
Ultimately, the study was terminated early due to lack 
of drug availability. At the time of study termination, all 
enrolled patients had been removed from study due to 
adverse events or disease progression, however 14/16 
(87%) of them remained alive receiving subsequent lines 
of therapy. mOS was 11.5 months (Figure 3), and median 
duration of follow-up was 11.5 months.
Discussion
Patients with advanced or metastatic pancreatic cancer 
face limited effective treatment options. The two most 
commonly used front-line regimens, gemcitabine/nab-
paclitaxel and FOLFIRINOX, yield response rates of 20–
30%, and mOS of 8.5 and 11.1 months (2,3). Gemcitabine/
nab-paclitaxel is less toxic, thus patients are often treated 
with front-line gemcitabine-containing regimens. 5-FU-
based regimens are often used for patients who progress on 
front-line gemcitabine therapy, supported by the superior 
efficacy of 5-FU and oxaliplatin (OFF) over best supportive 
care (BSC) in this setting (11). However, due to declining 
performance status, many patients are unable to receive 
oxaliplatin in the second-line setting, often treated with 
single-agent 5-FU or capecitabine. Thus, additional non-
toxic second-line regimens building on a fluoropyrimidine 
backbone are needed along with new molecular targets to 
provide meaningful improvements in outcome. 
Previous studies have investigated the aminopeptidase 
inhibitor tosedostat in elderly patients with relapsed/
Table 2 Treatment-related toxicities
Toxicity Grade 1/2 [%] Grade 3/4 [%] Any grade [%]
Anemia 2 [12] – 2 [12]
Acute coronary syndrome – 1 [6] 1 [6]
Diarrhea 5 [31] 1 [6] 6 [37]
Nausea 3 [18] 1 [6] 4 [25]
Mucositis 3 [18] – 3 [18]
Fatigue 3 [18] 1 [6] 4 [25]
Edema 3 [18] – 3 [18]
QT interval prolongation 3 [18] 1 [6] 4 [25]
Decreased left ventricle ejection fraction 5 [31] – 5 [31]
Thrombocytopenia 2 [12] – 2 [12]
Dizziness 2 [12] – 2 [12]
Maculopapular rash 2 [12] – 2 [12]
The denominator is the total number of patients.
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Figure 1 Treatment failure free survival and duration on study. (A) Shown is the treatment failure free survival for all patients; (B) shown 
is the duration on study of all patients. Eight patients remained on study with stable disease for greater than 3 months. Treatment was 
discontinued for progressive disease (#) or adverse events (*); one patient was censored (^) due to withdrawal of consent.
refractory AML, displaying CR or CR with incomplete 
platelet recovery (CRi) in 10% of patients (9). The first-in-
human phase I study of tosedostat monotherapy in advanced 
solid tumors demonstrated tolerability and preliminary 
efficacy in a subset of patients; however only one patient 
had pancreatic adenocarcinoma, precluding any definitive 
conclusions regarding its efficacy in this malignancy (10). 
To our knowledge, ours is the first study to evaluate an 
aminopeptidase inhibitor in combination with standard 
chemotherapy in advanced PDAC. 
Based on the phase Ib portion of our study, we identified 
the RP2D of tosedostat as 120mg oral twice daily with 
capecitabine 1,000 mg/m2 twice daily. The regimen was 
tolerable, with no grade-4 or grade-5 toxicities, and some 
grade-3 toxicities. However, there was a high incidence 
of low-grade asymptomatic decrease in EF, necessitating 
removal of 5/16 patients from study. Interestingly, three of 
those affected patients had high-normal baseline EF such 
that at their nadir, EFs remained in the near low-normal 
range, with an average EF decrease of 15%. No patients 
experienced congestive heart failure. Importantly, all 
occurrences of depressed EF were asymptomatic and self-
resolved with holding of therapy. This degree of cardiac 
toxicity is milder than that observed in a previous report 
of tosedostat in AML, wherein 3/73 patients (4%) were 
documented to experience congestive heart failure, where 
one patient received a daily dose of tosedostat 120 mg 
and two patients received a daily dose of 240 mg (9). At 
present, the mechanism of cardiotoxicity due to tosedostat 
is unknown. Together, these observations suggest caution is 
advised when treating patients with baseline heart disease, 
as well as frequent monitoring of patients without known 
heart disease.
The combination of tosedostat/capecitabine had 
moderate clinical benefit, with no patients experiencing a 
complete or partial response. However, the median TFFS 
was 3 months and median PFS was 7.0 months. These 
outcomes are encouraging for a second-line therapy, given 
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Figure 2 Progression free survival. Shown is the progression free 
survival of all patients on study.
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a median PFS of approximately 2 months in this setting, 
and they approximate that with standard of care first-line 
therapy. However, 8/16 patients experienced stable disease 
for greater than 3 months while on study. Given the median 
PFS of 3.1 months with nanoliposomal irinotecan/5-FU/
leucovorin, and 1.5 months with 5-FU/leucovorin in the 
second-line setting as reported in the NAPOLI-1 trial (4), 
this suggests that a subset of patients may be particularly 
susceptible to aminopeptidase inhibition. However, the 
enrollment of only 16 out of a planned 36 patients in our 
study presents a limitation to our data, due to early study 
closure. Given our small sample size, comparison to other 
published data is limited; a study with a larger sample 
size would be needed to confirm our findings. Among 
the eight patients with prolonged disease control on our 
study (greater than 3 months), two patients had an initial 
biochemical partial response (greater than 20% decrease 
of CA19-9 from baseline). Notably, those patients with 
prolonged disease control had variable durations of disease 
control on front-line chemotherapy, and three of them had 
amongst the highest baseline CA19-9 values, suggesting 
that benefit from the regimen is not an artifact of lower 
disease burden or general chemotherapy sensitivity; perhaps 
they are uniquely sensitive to amino acid deprivation due to 
unknown underlying molecular features. 
In conclusion,  tosedostat  in combination with 
capecitabine as a second-line treatment had an acceptable 
safety profile and displayed signs of efficacy in a subset of 
patients with advanced or metastatic PDAC. However, these 
conclusions are limited, as enrollment was less than 45% 
(16/36) of patients planned. Toxicities were manageable and 
did not preclude patients from pursuing subsequent lines 
of therapy, as 68% went on to further systemic therapy. 
These data suggest unique molecular susceptibilities to 
aminopeptidase inhibition in a subset of patients, and 
warrants further basic science and clinical investigation. 
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